Datasheet for ABIN965532

anti-AKT3 antibody

2 Publications

Go to Product page

Overview

Quantity:	0.1 mL
Target:	AKT3
Reactivity:	Human
Host:	Please inquire
Clonality:	Monoclonal
Conjugate:	This AKT3 antibody is un-conjugated
Application:	Western Blotting (WB), ELISA

Product Details

Specificity:	Ni-NTA purified truncated recombinant Akt3 expressed in E. Coli strain BL21 (DE3)
Purification:	Crude ascites.

Target Details

Target:	AKT3
Alternative Name:	Akt3 (AKT3 Products)
Background:	Akt3 (also designated protein kinase B gamma or vakt murine thymoma viral oncogene homolog 3),with 479-amino acid protein (about 53kDa), belongs to the AKT serine/threonine protein kinase family, which also includes Akt1 and Akt2. AKT kinases are known to be regulators of cell signaling in response to insulin and growth factors. They are involved in a wide variety of biological processes including cell proliferation, differentiation, apoptosis, tumorigenesis, as well as glycogen synthesis and glucose uptake.Akt3 is not required for the

Target Details

	maintenance of normal carbohydrate metabolism but is essential for the attainment of normal organ size. Identifying Akt3 as a selective target in melanoma cells also provides new therapeutic opportunities for patients in the advanced stages of this disease.
Gene ID:	10000
Pathways:	PI3K-Akt Signaling, RTK Signaling, TLR Signaling, Hepatitis C, VEGF Signaling

Application Details

Application Notes:	Western Blot: 1: 500- 1: 2000 ELISA: Propose dilution 1: 10,000. Determining optimal working dilutions by titration test.
Restrictions:	For Research Use only

Handling

Format:	Liquid
Storage:	-20 °C

Publications

Product cited in:	Easton, Cho, Roovers, Shineman, Mizrahi, Forman, Lee, Szabolcs, de Jong, Oltersdorf, Ludwig, Efstratiadis, Birnbaum: "Role for Akt3/protein kinase Bgamma in attainment of normal brain size." in: **Molecular and cellular biology**, Vol. 25, Issue 5, pp. 1869-78, (2005) (PubMed). Stahl, Sharma, Cheung, Zimmerman, Cheng, Bosenberg, Kester, Sandirasegarane, Robertson: " Deregulated Akt3 activity promotes development of malignant melanoma." in: **Cancer research**, Vol. 64, Issue 19, pp. 7002-10, (2004) (PubMed).